SG Americas Securities
HOWL icon

SG Americas Securities’s Werewolf Therapeutics HOWL Stock Holding History

SG Americas Securities’s Portfolio HOWL Stock Details HOWL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-13,779
Closed -$20K – 3588
2024
Q4 		$20K Buy
13,779
+262
+2% +$534 ﹤0.01% 3011
2024
Q3 		$29K Buy
+13,517
New +$30.7K ﹤0.01% 3323

Other funds holding HOWL

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

SG Americas Securities's HOWL Position: Q1 2025 in Review

SG Americas Securities sold out of Werewolf Therapeutics (HOWL) in Q1 2025, closing a stake of 13,779 shares — an estimated $20K sold.

SG Americas Securities first reported a position in HOWL in Q3 2024 and held it in 2 quarters. The position peaked at $29K in Q3 2024. 70 funds tracked by Wall St. Rank hold HOWL as of Q1 2025.

  • SG Americas Securities reported no remaining Werewolf Therapeutics position as of Q1 2025 after selling out during the quarter.
  • SG Americas Securities sold 13,779 Werewolf Therapeutics shares in Q1 2025, an estimated $20K.
  • SG Americas Securities first reported a position in Werewolf Therapeutics in Q3 2024 and held it in 2 quarters.
  • SG Americas Securities's Werewolf Therapeutics position peaked at $29K in Q3 2024.
  • 70 funds tracked by Wall St. Rank held Werewolf Therapeutics as of Q1 2025.

Based on SG Americas Securities's 13F filing for Q1 2025, filed 15 Apr 2025.